EP1556074A4 - CASEIN DERIVED PEPTIDES AND THEIR USE IN THERAPY - Google Patents

CASEIN DERIVED PEPTIDES AND THEIR USE IN THERAPY

Info

Publication number
EP1556074A4
EP1556074A4 EP02758768A EP02758768A EP1556074A4 EP 1556074 A4 EP1556074 A4 EP 1556074A4 EP 02758768 A EP02758768 A EP 02758768A EP 02758768 A EP02758768 A EP 02758768A EP 1556074 A4 EP1556074 A4 EP 1556074A4
Authority
EP
European Patent Office
Prior art keywords
therapy
derived peptides
casein derived
casein
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02758768A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP1556074A2 (en
Inventor
Zvi Sidelman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chay 13 Medical Res Group NV
Original Assignee
Chay 13 Medical Res Group NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/942,121 external-priority patent/US20020147144A1/en
Application filed by Chay 13 Medical Res Group NV filed Critical Chay 13 Medical Res Group NV
Publication of EP1556074A2 publication Critical patent/EP1556074A2/en
Publication of EP1556074A4 publication Critical patent/EP1556074A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4732—Casein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • AIDS & HIV (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Emergency Medicine (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP02758768A 2001-08-30 2002-08-29 CASEIN DERIVED PEPTIDES AND THEIR USE IN THERAPY Withdrawn EP1556074A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/942,121 US20020147144A1 (en) 2000-03-01 2001-08-30 Casein derived peptides and uses thereof in therapy
US942121 2001-08-30
PCT/IL2002/000720 WO2003018606A2 (en) 2001-08-30 2002-08-29 Casein derived peptides and uses thereof in therapy

Publications (2)

Publication Number Publication Date
EP1556074A2 EP1556074A2 (en) 2005-07-27
EP1556074A4 true EP1556074A4 (en) 2008-05-07

Family

ID=25477603

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02758768A Withdrawn EP1556074A4 (en) 2001-08-30 2002-08-29 CASEIN DERIVED PEPTIDES AND THEIR USE IN THERAPY

Country Status (15)

Country Link
EP (1) EP1556074A4 (enExample)
JP (1) JP2005511499A (enExample)
KR (1) KR20040078639A (enExample)
CN (1) CN1694719A (enExample)
AU (1) AU2002324323A2 (enExample)
BR (1) BR0212625A (enExample)
CA (1) CA2458924A1 (enExample)
CZ (1) CZ2004335A3 (enExample)
HU (1) HUP0500995A3 (enExample)
IL (1) IL160548A0 (enExample)
MX (1) MXPA04001890A (enExample)
NO (1) NO20040880L (enExample)
PL (1) PL375113A1 (enExample)
WO (1) WO2003018606A2 (enExample)
ZA (1) ZA200401574B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0313892D0 (en) * 2003-06-16 2003-07-23 Hannah Res Inst Control of lactation
AU2005209845A1 (en) * 2004-01-30 2005-08-18 Chemgenex Pharmaceuticals, Inc. Naphthalimide dosing by N-acetyl transferase genotyping
BRPI0507822A (pt) * 2004-03-01 2007-07-10 Peptera Pharmaceuticals Ltd método e composição farmacêutica para a prevenção ou o tratamento de uma doença ou uma condição autoimune ou infecciosa, método e composição farmacêutica para a prevenção ou o tratamento de uma doença ou uma condição do sangue, método e composição farmacêutica para modular a formação de células do sangue, método e composição farmacêutica para intensificar a mobilização periférico da célula tronco, método e composição farmacêutica para a prevenção ou o tratamento de uma doença ou uma condição metabólica, método e composição farmacêutica para a prevenção ou o tratamento das condições associadas com doses mieloablativas de quimioradioterapia suportadas pelo transplante autólogo de medula óssea ou de células tronco do sangue periférico (asct) ou pelo transplante alogenéico de medula óssea (bmt), método e composição farmacêutica para aumentar o efeito de um fator estimulante de células do sangue, método e composição farmacêutica para intensificar a colonização de células tronco do sangue doadas em um receptor mieloablatado, método e composição farmacêutica para a prevenção ou o tratamento de uma doença ou uma condição bacteriana, composição farmacêutica para o tratamento ou a prevenção de uma indicação selecionada do grupo que consiste em doença ou condição autoimune, doença viral, infecção viral, doença hematológica, deficiências hematológicas, trombocitopenia, pancitopenia, granulopenia, hiperlipidemia, hipercolesterolemia, glucosuria, hiperglicemia, diabetes, aids, hiv-1, distúrbios de células t auxiliares, deficiências de células dendrìticas, deficiências de macrofagos, distúrbios de células tronco hematopoiéticas incluindo distúrbios com plaquetas, linfócitos, células do plasma e neutrófilos, condições pré-leucêmicas, condições leucêmicas, distúrbios do sistema imunológico resultantes da terapia de quimioterapia ou de radiação, distúrbios do sistema imunológico humano resultantes do tratamento das doenças de deficiência imunológica e infecções bacterianas, composição farmacêutica para o tratamento ou a prevenção de um indicação selecionada do grupo que consiste em doença hematológica, deficiências hematológicas, trombocitopenia, pancitopenia, granulopenia, deficiências de células dendrìticas, deficiências de macrofagos, distúrbios de células tronco hematopoiéticas incluindo distúrbios com plaquetas, linfócitos, células do plasma e neutrófilos, condições pré-leucêmicas, condições leucêmicas, sìndrome mielodisplástiacas, malignidades não mielóides, anemia plástica e insuficiência da medula óssea, peptìdeo purificado, peptìdeo quimérico purificado, peptìdeo quimérico, composição farmacêutica, composição farmacêutica para a prevenção ou o tratamento de uma condição associada com um agente infeccioso de sars, método de processamento a baixa temperatura de hidrolisato proteolìtico de caseìna e hidrolisato de proteìna de caseìna
GB0423352D0 (en) 2004-10-21 2004-11-24 Hannah Res Inst "Control of mammary cell number"
ES2319475B1 (es) * 2005-06-08 2010-02-16 Consejo Superior Investig. Cientificas Peptidos bioactivos identificados en hidrolizados enzimaticos de caseinas lacteas y procedimiento de obtencion.
WO2007142230A1 (ja) 2006-06-09 2007-12-13 Morinaga Milk Industry Co., Ltd. 脂質代謝改善剤
JP2011026213A (ja) * 2009-07-22 2011-02-10 Snow Brand Milk Prod Co Ltd １型糖尿病抑制ペプチド
RU2645085C2 (ru) * 2012-04-16 2018-02-15 Дзе Кливленд Клиник Фаундейшн Мультивалентная вакцина против рака молочной железы
EP3590519A4 (en) * 2017-03-03 2020-12-16 Morinaga Milk Industry Co., Ltd. GLP-1 SECRETAGOGUE AND COMPOSITION
CN107814835B (zh) * 2017-12-01 2020-04-28 熊猫乳品集团股份有限公司 一种生物活性多肽avpitptlnreq及其制备方法和应用
CN108017709B (zh) * 2017-12-12 2020-04-10 浙江辉肽生命健康科技有限公司 一种生物活性多肽kepmigvnqela及其制备方法和应用
CN113952446B (zh) * 2021-09-03 2023-12-05 河南省医药科学研究院 生物活性肽在抑制骨髓毒性中的应用
CN120815163B (zh) * 2025-09-16 2025-12-12 华中科技大学同济医学院附属同济医院 能抑制ccnb2表达的抗肿瘤药物和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2118134A1 (enExample) * 1970-12-16 1972-07-28 Assad Najjar V
WO2001064234A1 (en) * 2000-03-01 2001-09-07 Chay 13 Medical Research Group N.V. Casein derived peptides and uses thereof in therapy

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ332993A (en) * 1997-03-21 2000-01-28 Snow Brand Milk Products Co Ltd Iron-casein complex hydrolyzate and process for the production thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2118134A1 (enExample) * 1970-12-16 1972-07-28 Assad Najjar V
WO2001064234A1 (en) * 2000-03-01 2001-09-07 Chay 13 Medical Research Group N.V. Casein derived peptides and uses thereof in therapy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KARIYA K ET AL: "INHIBITION OF ANGIOTENSIN CONVERTING ENZYME OF RAT BRAIN WITH BRADYKININ AND ITS FRAGMENTS", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS, SAN DIEGO, CA, US, vol. 100, no. 1, 1981, pages 31 - 36, XP008066034, ISSN: 0006-291X *

Also Published As

Publication number Publication date
MXPA04001890A (es) 2004-06-18
ZA200401574B (en) 2007-02-28
CA2458924A1 (en) 2003-03-06
NO20040880L (no) 2004-04-20
HUP0500995A2 (en) 2007-05-02
WO2003018606A3 (en) 2005-05-06
PL375113A1 (en) 2005-11-28
HUP0500995A3 (en) 2008-09-29
WO2003018606A2 (en) 2003-03-06
BR0212625A (pt) 2007-06-19
WO2003018606A9 (en) 2004-04-08
IL160548A0 (en) 2004-07-25
CN1694719A (zh) 2005-11-09
JP2005511499A (ja) 2005-04-28
AU2002324323A2 (en) 2003-03-10
EP1556074A2 (en) 2005-07-27
CZ2004335A3 (cs) 2004-07-14
KR20040078639A (ko) 2004-09-10

Similar Documents

Publication Publication Date Title
HUP0301003A3 (en) Casein derived peptides and uses thereof in therapy
HUP0500992A3 (en) Tacis and br3 polypeptides and uses thereof
EP1461605A4 (en) NANOSTERIALS OF PROTEINS AND PEPTIDES
HUP0500989A2 (en) Animicrobial polypeptides and their uses
AU2002346504A8 (en) Therapeutic protein and treatments
EP1414848A4 (en) REPLICINE PEPTIDES AND ITS USES
HUP0500995A2 (en) Casein derived peptides and uses thereof in therapy
SI1462455T1 (sl) Ser-Ser-Ser-Arg Peptid in zdravilna uporaba le-tega
WO2003099841A9 (en) Peptides and the use thereof in darkening the skin
EP1419175A4 (en) PEPTIDES OF REPLIKIN AND THEIR USE
AU2002233457A1 (en) Non-glycosylated peptides derived from the rsv g protein and use thereof in a vaccine
IL131707A0 (en) Acetylcholinesterase-derived peptides and uses thereof
GB9918155D0 (en) Proteins and peptides
GB0026134D0 (en) Peptides and their use
EP1080185A4 (en) BASIC PROTEIN PEPTIDES OF MYELIN AND THE USE THEREOF.
IL144225A0 (en) ((aminoiminomethyl) amino) alkanecarboxamides and their applications in therapy
IL151351A0 (en) Casein derived peptides and uses thereof in therapy
HK1051501A (en) Casein derived peptides and uses thereof in therapy
GB0102447D0 (en) Protein variants and uses thereof
SG10201403662QA (en) Replikin peptides and uses thereof
GB0108752D0 (en) Peptide epitopes and uses thereof
IL159495A0 (en) Replikin peptides and uses thereof
IL158109A0 (en) Replikin peptides and uses thereof
AU2001274923A1 (en) Novel human thrombospondin-like proteins and polynucleotides encoding the same
GB0017028D0 (en) Peptides and their therapeutic use

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040313

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20080403

17Q First examination report despatched

Effective date: 20080714

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090127